Argo Medical aims to fundamentally change the lives of individuals with spinal cord injuries. The document discusses the negative impacts of spinal cord injuries based on a 1947 quote, including issues with bladder, bones, blood, skin, bowels, and mental health. It provides statistics on the prevalence and costs of spinal cord injuries. Argo Medical's exoskeleton technology aims to allow independent walking, individual control, and all-day use to improve health, independence, and social inclusion for users. Clinical studies show benefits like increased lean muscle mass, decreased fat mass, and improved bowel function for users. The technology has significant potential cost savings for health systems and a large potential commercial market.

1. Mission
Argo Medical aims to
fundamentally change
the health and life
experiences of
individuals with spinal
cord injury.

2. The Impact of a Spinal Cord Injury….
“the pathetic [paralyzed] patient lying long in a
bed, the urine leaking from his distended
bladder, the lime leaking from his bones, the
blood clotting in his veins, the flesh rotting from
his seat, the scybala stacking up in his colon, the
spirit draining from his soul”…. British Medical
Journal; ii:967-8, 1947.
Dr. Richard Alan J. Asher, an eminent British Endocrinologist
and Haematologist during the 20th Century

3. Clinical / Impact SCI
“the pathetic [paralyzed] patient lying long in a
bed, the urine leaking from his distended
bladder, the lime leaking from his bones, the
blood clotting in his veins, the flesh rotting from
his seat, the scybala stacking up in his colon, the
spirit draining from his soul”…. British Medical
Journal; ii:967-8, 1947.
Dr. Richard Alan J. Asher, an eminent British Endocrinologist
and Haematologist during the 20th Century

4. Spinal Cord Injury = High Expense / Use at Home
•
•
•
•
•
•
~6 million US/Europe in Wheelchairs
181,000 Registered SCI Germany
42,000 are active in the VA system
50% of injuries occur at age of 16 to 30
Lifetime SCI complications costs range
from $681k to over $3 million
87.9% of all spinal cord injured
individuals discharged to private
homes
*2011 Statistics from Christopher Reeve
Foundation
**QUERI Fact Sheet, April 2012

5. Current Patients T1 and below
Tetraplegia:
Spinal cord lesion at C8 or
above resulting in
complete or incomplete
paralysis of the arms and
legs
Paraplegia:
Spinal cord lesion at T1 or
below resulting in
complete or incomplete
paralysis of the legs

6. Design Goals
• Health Improvement allowing
physical activities that have
been lost or diminished
• Restoration of more control of
their living environment: regain
self-sufficiency and
independence
• Increase inclusion

7. The Platform / Features
• Independent
walking –
stairs
• Individual
control
• Carries own
weight
• Works in
multiple
environments
• All day use

8. How it works:
Computer,
software, &
Batteries
Communicator to
select functions
Tilt Sensor for
operating functions
Pelvic Support
Manual Buttons
Motors, Gears,
software
Crutches
- Sensing
ground
- Safety

9. A Day in Radi’s (New) Life
The Market
of Akko

10. Technion alumni did. In May 2012, paraplegic Claire Lomas finished the London
Marathon in 16 days using ReWalk, a lightweight, computer-assisted exoskeleton

11. PM Netanyahu & President Obama
Jerusalem, March 2013
Technion, Haifa, June 2012

12. Clinical Data / Experience

13. Clinical Studies
Safety and Function / Regulatory
Long Term Medical Benefits
• Multicenter study of 24 patients:
o Moss Rehab. (US)
o Sheba Medical Center (Israel)
o Villa Baretta (Italy)
• Ongoing single center study of 20
patients:
o James J. Peters VA (Bronx, NY)
• Primary Outcomes:
o Safety A/E’s
o Tolerance
o Ease of use
• Primary Outcomes:
o Measure medical/clinical benefits
of vertical loading and walking
with exoskeleton technology:

bowel function,

urinary tract function,

body composition,

metabolism
Further studies: Rancho (Calif.); Stoke (UK);
Murneau (Germany)

14. Ongoing Medical Benefits Study
Experience

15. Percent Change in Lean Tissue Mass (n=3)
VA Bronx, New York, Interim Data, Medical Benefits Study 2012

16. Mean Fat Mass Loss after Exoskeletal-Assisted
Walking (N=5)
VA Bronx, New York, Interim Data, Medical Benefits Study 2012

17. Participant #
Health Benefits
Number of
Sessions when
the changes
were noted
Total Bowel
Evacuation Time
per Bowel Day
Bowel Evacuation
Bristol Stool Scale
(frequency per week)
(1=hard to 7=liquid; 4-6 ideal)
1
18
↓ from 90 to
30 min
↑ from 1-2 to
3-4x/week
Change from 3
to 4
No reported change in bowel
medications
5
15
15 to 30 min,
no change
↑ from 1-2 to
3-4x/week
Change from 2
to 4
Discontinuation of laxative
(Dulcolax)
16
↓ from 60 to
30 min
↑ from 2-3 to
3-4x/week
Change from 1
to 4
Discontinuation of the use of a
stool softener (Colace) and
laxative (Senna)
Change from 4
to 5
Reduction in use of a stool
softener (Colace) and/or a
laxative (Senna) from weekly to
≤1x/month
6
7
9
↑ from 2-3 to
3-4x/week
16
↓ from 90 to
<30 min
20
Bowel program was
Change from 3 to
↓ from 120 to performed 6-7x/wk to
4; ↓ in amount
45 min
avoid accidents; able to ↓
of liquid leakage
to 3-4x/wk
VA Bronx, New York, Interim Data, Medical Benefits Study 2012
Bowel Specific
Medication Use
Eliminated laxative use and
decreased amount of
additional dietary fiber
supplements

18. Business Case

19. What are the benefits of walking again?
Health Impact
Cardiovascular (lower risk of heart attack,
diabetes, high blood pressure, stroke)
Improved bone density
Better GI track function
Weight control
Social
Inclusion in society
Self esteem
Economic
Reduction in medical cost
Capacity to work

20. SOLID RETURN ON INVESTMENT FOR PAYERS

PRE-REWALK:
Annualized SCI
data / ReWalkers
Survey of Cost
POST-REWALK:
Survey of cost
(n = 4)
Potential Annual
Reduction
Medications
22,792.39
10,712.88
12,039.51
Hospital based
therapy
17,748.00
0
17,748.00
Totals
40,540.39
10,712.88
29,787.51
1
Preliminary data from literature and survey of 4 ReWalkers
BOD 11 December 2012

21. LARGE POTENTIAL MARKET
ABI Research: Exoskeletons ~$300M in 2020
ABI Research: Exoskeletons, Powered Prostheses and Optical Sensory Devices 2010

22. Strong Intellectual Property Position
• Issued US Method / Apparatus IP with use
of tilt sensors for control – blocker for
competition – 14 years remaining
• Europe and selected Asia markets issued
Apparatus IP
• Internal & external reviews show freedom
to operate
• Multiple Divisionals and other filings
• Tetraplegic and other applications in place

23. Summary
•
•
•
•
•
•
•
•
Product launched!
Extensive lab testing; confirmatory clinical studies and
use
Over 400 trained representing >22,000 hours of use
Blocking patent position
Manufacturability scale-up in process
CE Clearance complete; FDA submission made
Global Management base in place
Strategic investment and partnership agreement with
Yaskawa Electric Japan

24. Thank You !